Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Omni Bio's New Mechanism For GvHD

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

On July 10, 2013, Omni Bio Pharmaceutical, Inc. (OTCPK:OMBP) announced it will be collaborating with the University of Michigan Cancer Center (UMCC) and Leukemia and Lymphoma Society (LLS) to study plasma-derived alpha-1 antitrypsin (p-AAT) for the treatment of complications following bone marrow transplantation, or as it's more commonly referred to, Graft vs. Host Disease (GvHD). The Phase II multicenter pilot study (ClinicalTrials.gov # NCT01700036) will be funded almost entirely by UMCC and LLS. Omni Bio will supply logistical support and drug will be supplied by CSL Behring.

The principal investigator of the study is Dr. Ravan R....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details